Table 1.
Patient characteristics.
| Parameter | No. of patients or range (median) | % |
|---|---|---|
| No. of patients | 1392 | |
| Age (year) | 20–83 (49) | |
| Observation period (months) | 0–120 (59) | |
| Death from any cause | 295 | |
| Disease recurrence | 449 | |
| FIGO 2018 stage | ||
| IIB | 313 | 22.5 |
| IIIC1p | 1003 | 72.1 |
| IIIC2p | 76 | 5.5 |
| pT classification | ||
| pTIa | 1 | 0.1 |
| pTIb | 495 | 35.6 |
| pT2a | 159 | 11.4 |
| pT2b | 737 | 52.9 |
| Histology | ||
| SCC | 954 | 68.5 |
| nSCC | 438 | 31.5 |
| PLN metastasis | ||
| Negative | 315 | 22.6 |
| Positive | 1077 | 77.4 |
| PALN metastasis | ||
| Negative | 259 | 18.6 |
| Positive | 76 | 5.5 |
| Lymphadenectomy not performed | 1057 | 75.9 |
| Tumor diameter | ||
| ≤ 40 mm | 867 | 62.3 |
| > 40 mm | 513 | 36.9 |
| Unknown | 12 | 0.9 |
| LVSI | ||
| Negative | 194 | 13.9 |
| Positive | 1143 | 82.1 |
| Unknown | 55 | 4.0 |
| Stromal invasion | ||
| ≤ 1/2 | 238 | 17.1 |
| > 1/2 | 1020 | 73.3 |
| Unknown | 134 | 9.6 |
| Ovarian metastasis | ||
| Negative | 1317 | 94.6 |
| Positive | 32 | 2.3 |
| Unknown/preserved` | 43 | 3.1 |
| Peritoneal cytology | ||
| Negative | 411 | 29.5 |
| Positive | 51 | 3.7 |
| Unknown/not examined | 930 | 66.8 |
| Uterine corpus invasion | ||
| Negative | 1053 | 75.6 |
| Positive | 321 | 23.1 |
| Unknown | 18 | 1.3 |
| Adjuvant therapy | ||
| CCRT | 573 | 41.2 |
| CT | 350 | 25.1 |
| RT | 351 | 25.2 |
| None | 64 | 4.6 |
| Others/unknown | 54 | 3.9 |
FIGO The International Federation of Gynecology and Obstetrics, HR hazard ratio, SCC squamous cell carcinoma, nSCC non-squamous cell carcinoma, PLN pelvic lymph node, LVSI lymphovascular space invasion, CCRT concurrent chemoradiotherapy, CT chemotherapy, RT radiotherapy.